BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35117223)

  • 1. Clinicopathological characteristics and treatment outcome in obese patients with diffuse large B-cell lymphoma.
    Wu YY; You JY; Huang CE; Hsu CC; Chen YY; Tsou HY; Chen YJ; Li CP; Lai YH; Lu CH; Chen PT; Chen CC
    Transl Cancer Res; 2020 Oct; 9(10):6116-6127. PubMed ID: 35117223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding MYC/BCL2 double expression to NCCN-IPI may not improve prognostic value to an acceptable level.
    Warnnissorn N; Kanitsap N; Niparuck P; Boonsakan P; Kulalert P; Limvorapitak W; Bhoopat L; Saengboon S; Suriyonplengsaeng C; Chantrathammachart P; Puavilai T; Chuncharunee S
    Blood Res; 2024 Feb; 59(1):2. PubMed ID: 38485822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of total lesion glycolysis and cell-of-origin subtypes for prognostic stratification of diffuse large B-cell lymphoma patients.
    Jiang C; Teng Y; Zheng Z; Zhou Z; Xu J
    Quant Imaging Med Surg; 2021 Jun; 11(6):2509-2520. PubMed ID: 34079720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 7. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
    Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
    Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
    Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
    Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
    Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
    [No Abstract]   [Full Text] [Related]  

  • 13. Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
    Antic D; Jelicic J; Trajkovic G; Balint MT; Bila J; Markovic O; Petkovic I; Nikolic V; Andjelic B; Djurasinovic V; Sretenovic A; Smiljanic M; Vukovic V; Mihaljevic B
    Ann Hematol; 2018 Feb; 97(2):267-276. PubMed ID: 29130134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma.
    Castro D; Beltrán B; Quiñones MDP; Pachas C; Huerta Y; Lalupu K; Mendoza R; Castillo JJ
    Leuk Res; 2021 Mar; 102():106513. PubMed ID: 33561632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
    Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
    Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.
    Niu JY; Tian T; Zhu HY; Liang JH; Wu W; Cao L; Lu RN; Wang L; Li JY; Xu W
    Ann Hematol; 2018 Oct; 97(10):1841-1849. PubMed ID: 29860562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
    Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
    Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
    Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.